Preclinical and clinical studies with the optimized cryptic peptide vaccine Vx-001, that targets the universal tumor antigen telomerase reverse transcriptase (TERT) have revealed its capacity to induce a cross-reactive immune response against the wild type (WT) cryptic peptide, which in turn can be amplified further with the WT peptide. This evidence concerns the gene TERT and neoplasm.